Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
HwMrMHCt5eYjMbm6
Listen
